Department of Dermatology, Pak Emirates Military Hospital, Rawalpindi, Pakistan.
Department of Dermatology, Pak Emirates Military Hospital, Rawalpindi.
J Ayub Med Coll Abbottabad. 2021 Jan-Mar;33(1):60-63.
Acne vulgaris has been a common clinical condition. Due to. high prevalence and unclear etio-pathogenesis of acne vulgaris, large number of treatment options have been available across the globe. Limited work has been done to explore the options which may manage or prevent these adverse effects and improve the adherence to the prescribed medications. We therefore conducted this trial to look for effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris.
To look for effectiveness of oral omega 3 in reducing mucocutaneous side effects of oral isotretinoin in patients with acne vulgaris. It was a randomized control trial conducted at Department of Dermatology Pak Emirates Military Hospital Rawalpindi. Ten months, June 2019 to May 2020.
A total of 60 patients of acne vulgaris put on oral isotretinoin by consultant dermatologist were included in the study. Patients were randomized into groups by lottery method. Group A received the placebo along with oral isotretinoin while Group B received oral omega 3 in standard dose in addition to oral isotretinoin. Comparison was made in both the groups regarding common mucocutaneous side effects.
Out of 60patients with acne vulgaris and put on isotretinoin included in the study, 26 (43.3%) received placebo in addition to isotretinoin while 34 (56.7%) received omega 3 in addition to isotretinoin. Forty (66.7%) patients were female while 20 (33.3%) were male. Cheilitis 35 (58.3%) was the commonest side effect followed by lip dryness 33 (55%). Application of chi-square test revealed that cheilitis, lip dryness and xerosis were significantly found in more patients who received placebo as compared to those who received omega 3 along with isotretinoin.
Mucocutaneous side effects were a very common finding among patients of acne vulgaris managed with isotretinoin. Cheilitis was the most reported mucocutaneous side effects among the target population. This RCT demonstrated that omega 3 was superior to placebo in order to prevent or manage cheilitis, xerosis or dry lips.
痤疮是一种常见的临床病症。由于痤疮的高发病率和不明病因，全球有大量的治疗选择。然而，对于可能管理或预防这些不良反应并提高患者对处方药物的依从性的治疗选择，相关工作还很有限。因此，我们进行了这项试验，以探讨口服欧米伽 3 对痤疮患者口服异维 A 酸引起的黏膜皮肤副作用的疗效。
探讨口服欧米伽 3 对痤疮患者口服异维 A 酸引起的黏膜皮肤副作用的疗效。这是一项在巴基斯坦拉瓦尔品第的巴基斯坦阿联酋军事医院皮肤科进行的随机对照试验。试验时间为 2019 年 6 月至 2020 年 5 月，共 10 个月。
共纳入 60 例接受皮肤科顾问开具的口服异维 A 酸治疗的痤疮患者。采用随机数表法将患者分为两组。A 组患者接受安慰剂联合口服异维 A 酸治疗，B 组患者接受标准剂量的口服欧米伽 3 联合口服异维 A 酸治疗。比较两组患者常见的黏膜皮肤副作用。
在纳入研究的 60 例接受异维 A 酸治疗的痤疮患者中，有 26 例（43.3%）患者在接受异维 A 酸治疗的同时接受安慰剂治疗，34 例（56.7%）患者在接受异维 A 酸治疗的同时接受口服欧米伽 3 治疗。40 例（66.7%）患者为女性，20 例（33.3%）为男性。唇炎（58.3%）是最常见的副作用，其次是唇干（55%）。应用卡方检验显示，接受安慰剂治疗的患者黏膜皮肤副作用，如唇炎、唇干和皮肤干燥，比接受口服欧米伽 3 联合异维 A 酸治疗的患者更为常见。
接受异维 A 酸治疗的痤疮患者常出现黏膜皮肤副作用。唇炎是目标人群中报告最多的黏膜皮肤副作用。这项 RCT 表明，口服欧米伽 3 优于安慰剂，可预防或治疗唇炎、皮肤干燥或唇干。
